Prevalence and significance of HER‐2/neu expression in early epithelial ovarian cancer

Background. Although expression of the HER‐2/neu oncogene may be of some prognostic importance in advanced ovarian cancer, its role in early‐stage disease has not been established. The current study examined the prevalence and significance of HER‐2/neu expression in early epithelial ovarian cancer.

[1]  D. Eccles,et al.  Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. , 1992, Oncogene.

[2]  S Toikkanen,et al.  Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.

[5]  R. Koski,et al.  Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit , 1992, Cell.

[6]  Yosef Yarden,et al.  Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.

[7]  C. Cordon-Cardo,et al.  HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. , 1992, Anticancer research.

[8]  D. Carter,et al.  NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. , 1992, Gynecologic oncology.

[9]  K. Dobashi,et al.  Characterization of a neu/c-erbB-2 protein-specific activating factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Gusterson,et al.  An immunohistochemical study of the incidence and significance of C-erbB-2 oncoprotein overexpression in ovarian neoplasia , 1991, International Journal of Gynecologic Cancer.

[11]  R. Akita,et al.  An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. , 1991, Cancer research.

[12]  W. Gullick,et al.  c‐erbB‐2 oncogene expression in ovarian cancer , 1990, The Journal of pathology.

[13]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[14]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[15]  J. Moreau,et al.  Detection of proto-oncogenes in the genome of the amphibian Xenopus laevis. , 1989, Oncogene.

[16]  M. Greene,et al.  The neu (c-erbB-2) oncogene. , 1989, Seminars in oncology.

[17]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[18]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[19]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  S. Rubin,et al.  Prognostic significance of HER‐2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis , 1993, American journal of obstetrics and gynecology.